Business Context and Reporting Period
This Form 8-K is a current report filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on February 14, 2019. The filing discloses a corporate action involving a reverse stock split of the Company's common stock, authorized by stockholders at a Special Stockholder Meeting held on February 12, 2019.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a capital structure change rather than financial performance results.
Material Changes
- Reverse Stock Split: The Company implemented a 1-for-6 reverse stock split effective at 12:01 a.m. on February 19, 2019.
- Share Consolidation: Six (6) shares of common stock issued and outstanding were combined into one (1) validly issued, fully paid, and non-assessable share.
- Par Value: The par value per share remains unchanged at $0.0001.
- Fractional Shares: No fractional shares were issued; holdings were rounded up to the next whole share.
- Trading Status: Common stock began trading on a split-adjusted basis on February 20, 2019, under the existing symbol "TROV".
Guidance, Outlook, and Risks
The filing does not contain management commentary on future guidance, outlook, risks, contingencies, or unusual items. The document serves strictly to notify the market of the amendment to the Certificate of Incorporation and the execution of the reverse stock split.
Investor Verification Checklist
- Verify the post-split share count and ownership percentage adjustments in brokerage accounts.
- Confirm the trading symbol "TROV" and the effective trading date of February 20, 2019.
- Review the press release (Exhibit 99.1) for any additional context on the rationale for the split.
- Check subsequent filings for any impact on the Company's compliance with stock exchange listing requirements.